NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
View Top Employees from NervGen Pharma Corp.Website | http://www.nervgen.com |
Revenue | $924000 |
Employees | 18 (14 on RocketReach) |
Founded | 2018 |
Address | 2955 Virtual Way, 480, Vancouver, British Columbia V5M 4X6, CA |
Phone | (604) 488-5421 |
Technologies |
JavaScript,
HTML,
PHP
+18 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular NervGen Pharma Corp. employee's phone or email?
The NervGen Pharma Corp. annual revenue was $924000 in 2024.
Bill Adams is the CFO of NervGen Pharma Corp..
14 people are employed at NervGen Pharma Corp..
NervGen Pharma Corp. is based in Vancouver, British Columbia.
The NAICS codes for NervGen Pharma Corp. are [325, 32541, 32, 3254].
The SIC codes for NervGen Pharma Corp. are [283, 28].